| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Oncology | ||
Phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Oncology | ||
Phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
Relmada Therapeutics, Inc.$6.41
-0.1 (-1.54%)
C 49Pipeline Score Fair Value Pharma · Clinical
Market Cap
738.43 M
EPS
-1.11
P/E Ratio
-
Value Trade
5.05 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
8.09 M
Operating CF
-15.07 M
Total Assets
235.36 M
Total Liabilities
16.63 M
Equity
218.73 M
D/E Ratio
12,345
-2.09 %
Week
-2.49 %
1 Month
64.1 %
3 Month
63.72 %
6 Month
-81.38 %
5 Year
-73.89 %
All Time
Cash Data
Cash Position
233.96 M
Monthly Burn
5.02 M
Runway
44.6 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
1.44 M
52 Week Range
0.52 - 8
% held by Insiders
13.8 %
% held by Institutions
71.9 %
Enterprise Value
504.46 M
Total Shares
104.88 M
Short %
11.58 %
Float Shares
91.98 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Relmada Therapeutics, Inc.
227Total events
0Upcoming
61Tier-1 (high impact)
2014 – 2026Coverage
Event history 227
Jun 26, 2026
▲Quarterly UpdateCorporate
Relmada Therapeutics added to Russell 2000 and Russell 3000 indexes
Jun 11, 2026
▲Management ChangeCorporate
Appointment of Michael Quirk as Senior Advisor for Sepranolone Program
Jun 4, 2026
◆Oral PresentationPresentation
Relmada Therapeutics to present at Jefferies Global Healthcare Conference
Jun 2026
◆Trial InitiationNDV-01Trial
Phase 3 RESCUE registrational program initiation
Intermediate-Risk NMIBCsource ↗
May 17, 2026
◆Oral PresentationNDV-01Presentation
Trials-in-Progress oral presentation of Phase 3 RESCUE program overview at AUA2026
Intermediate-Risk NMIBCsource ↗
May 15, 2026
◆Poster PresentationNDV-01Presentation
Poster presentation of 12-month Phase 2 data in High-Risk NMIBC at AUA2026
High-Risk NMIBCsource ↗
May 12, 2026
▲Full ResultsNDV-01Clinical Data
Positive 12-month Phase 2 data for NDV-01 in NMIBC
high-risk non-muscle invasive bladder cancer (NMIBC)source ↗
May 12, 2026
●Oral PresentationNDV-01Presentation
Phase 3 RESCUE program design presentation at AUA2026
non-muscle invasive bladder cancer (NMIBC)source ↗
Q2 2026
◆IND ClearanceNDV-01IND
Expected US IND clearance for NDV-01
non-muscle invasive bladder cancer (NMIBC)source ↗
Q2 2026
●Trial InitiationNDV-01Trial
Initiation of Phase 3 RESCUE registrational program for NDV-01
non-muscle invasive bladder cancer (NMIBC)source ↗
Q2 2026
◆Trial InitiationsepranoloneTrial
Sepranolone Phase 2 initiation in Prader-Willi syndrome
Prader-Willi syndromesource ↗
Drug Pipeline Intelligence
C49
Pipeline Score $872M
Pipeline ValueFair Value
Valuation Signal2
Drugs Scored1.2x
rNPV / MCap Top 72%
Micro Cap (rank 256 of 912)
Percentile RankRelmada Therapeutics, Inc. carries a moderate pipeline score (49/100), with $2.2B risk-adjusted pipeline value, led by REL-1017 in Major Depressive Disorder (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REL-1017 Small molecule | Major Depressive Disorder | Phase 3 | NCT05081167 | 49% | $1.3B | COMPLETED | 1,086 | - | - | Sep 14, 2022 | - | Mar 26, 2024 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
NDV-01 | high-risk non-muscle invasive bladder cancer | Phase 2 | 2026-05-05 | 9-month Complete Response Data | Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026 | |
NDV-01 | high-risk non-muscle invasive bladder cancer | Phase 2 | 2026-05-05 | 9-month Complete Response Data | Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026 | |
NDV-01 | high-risk non-muscle invasive bladder cancer | Phase 2 | 2026-05-05 | 9-month Complete Response Data | Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in RLMD
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
RLMD Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
RLMDRelmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes
Relmada Therapeutics announced its inclusion in the Russell 2000 and Russell 3000 Indexes, effective June 26, 2026. This milestone reflects the company's progress and robust financial standing, particularly in relation to its lead candidate NDV-01. The Russell 3000 Index is a key benchmark for U.S. equity performance, covering a significant portion of the market.
Read more →RLMDRelmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program
Relmada Therapeutics has appointed Dr. Michael Quirk as Senior Advisor for its sepranolone program. With over 20 years of experience in neuroscience drug development, Dr. Quirk aims to advance sepranolone, a GABA receptor modulator targeting Prader-Willi Syndrome and other CNS disorders. His expertise is expected to be crucial in navigating the clinical development of this promising therapy.
Read more →RLMDRelmada Therapeutics to Present at the Jefferies Global Healthcare Conference
Relmada Therapeutics will present at the Jefferies Global Healthcare Conference from June 2-4, 2026. CEO Sergio Traversa and CFO Maged Shenouda will participate in a fireside chat on June 4. The company is focused on developing therapies for oncology and central nervous system disorders, with promising candidates in mid-stage clinical development.
Read more →RLMDRelmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Relmada Therapeutics reported strong Phase 2 data for NDV-01, showing a 95% complete response rate in high-risk NMIBC patients. The company is on track to initiate the Phase 3 RESCUE program in mid-2026 and has secured a $160 million PIPE financing to support its operations through 2029. Additionally, a provisional patent application for NDV-01 has been filed, potentially extending patent protection until 2047.
Read more →RLMD▲ +6.9%on this news
Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026
Relmada Therapeutics, a clinical-stage biotechnology company, will report its first quarter 2026 financial results on May 12, 2026. The company will host a conference call and webcast at 4:30 PM ET to discuss these results and recent business progress. Relmada focuses on therapies for oncology and central nervous system disorders.
Read more →RLMDRelmada Therapeutics to Present NDV-01 Abstracts at AUA2026
Relmada Therapeutics will present two abstracts on NDV-01 at AUA2026, including 12-month Phase 2 data for high-risk non-muscle invasive bladder cancer (NMIBC) and an overview of the upcoming Phase 3 'RESCUE' program. The presentations are scheduled for May 15 and May 17, 2026, in Washington D.C. NDV-01 is designed to improve treatment outcomes in NMIBC.
Read more →RLMDRelmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update
Relmada Therapeutics reported its fourth quarter and full year 2025 results, highlighting substantial advancements in its lead program, NDV-01, for treating non-muscle invasive bladder cancer. The company noted promising 12-month data demonstrating durable responses and a favorable safety profile. With a successful financing round and FDA alignment on development pathways, Relmada is poised to initiate the Phase 3 RESCUE program in mid-2026.
Read more →RLMDRelmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026
Relmada Therapeutics has announced a conference call scheduled for March 19, 2026, to discuss its fourth-quarter financial results for 2025. The call will provide insights into the company's recent business progress and developments in its clinical-stage therapies. Relmada focuses on innovative treatments for oncology and central nervous system disorders.
Read more →RLMD▲ +61.1%on this newsshared move
Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing
Relmada Therapeutics has announced a successful oversubscribed private placement financing, raising approximately $160 million. The financing involves the sale of common stock and pre-funded warrants, with participation from several prominent investors. The funds will be utilized for working capital and advancing the company's research and development efforts.
Read more →RLMD▲ +61.1%on this newsshared move
Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer
Relmada Therapeutics reported promising 12-month interim data for NDV-01 in a Phase 2 trial for high-risk non-muscle invasive bladder cancer (NMIBC). The treatment demonstrated a 76% complete response rate, with an 80% rate in BCG-unresponsive patients. The safety profile remains favorable, with no severe adverse events reported. These results support the advancement of NDV-01 into a Phase 3 registrational program expected to start in mid-2026.
Read more →RLMD▲ +61.1%on this newsshared move
Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference
Relmada Therapeutics, Inc. has announced its participation in the Leerink Partners Global Healthcare Conference taking place from March 8-11, 2026, in Miami, Florida. CEO Sergio Traversa and CFO Maged Shenouda will engage in a fireside chat on March 10. The company will also offer opportunities for one-on-one meetings with investors during the event. This participation highlights Relmada's ongoing efforts to connect with the investment community and discuss its clinical-stage therapies.
Read more →RLMDRelmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications
Relmada Therapeutics has announced regulatory feedback from the FDA aligning on the design for registrational studies of NDV-01, aimed at treating non-muscle invasive bladder cancer (NMIBC). The FDA has approved a single-arm trial for high-grade, BCG-unresponsive NMIBC and a randomized study for intermediate-risk NMIBC. Both studies are expected to start in the first half of 2026. The company views this as a significant step forward in developing a potentially transformative therapeutic option for patients with limited treatment alternatives.
Read more →RLMDRelmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology
Relmada Therapeutics announced the presentation of 6-month follow-up data from its Phase 2 trial of NDV-01 for non-muscle invasive bladder cancer (NMIBC) at the Society for Urologic Oncology meeting. The data indicates a 92% complete response rate, and the company plans to initiate Phase 3 studies in H1 2026. NDV-01 is designed to provide a bladder-sparing treatment option for patients.
Read more →RLMDRelmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates
Relmada Therapeutics reported strong third quarter results, highlighting a 92% response rate for NDV-01 in non-muscle invasive bladder cancer (NMIBC). The company secured FDA alignment for a Phase 3 program with two distinct paths for approval. Additionally, a $100 million financing was completed to support ongoing operations and clinical trials. The company aims to initiate registrational studies in the first half of 2026.
Read more →RLMDRelmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025
Relmada Therapeutics, a clinical-stage biotechnology company, will report its third quarter 2025 financial results on November 13, 2025. The company is focused on developing therapies for oncology and central nervous system conditions. A conference call and webcast will provide insights into their financial performance and recent business developments.
Read more →RLMD▲ +25.9%on this newsshared move
Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Relmada Therapeutics has announced the pricing of its underwritten offering, totaling $100 million. The offering includes 40,142,000 shares of common stock priced at $2.20 each, along with pre-funded warrants. The proceeds will be utilized for working capital, clinical studies, and potential acquisitions. The offering is set to close on November 5, 2025.
Read more →RLMD▲ +25.9%on this newsshared move
Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer
Relmada Therapeutics received FDA feedback endorsing two registrational study paths for NDV-01 in non-muscle invasive bladder cancer (NMIBC). The FDA confirmed that no additional non-clinical studies are needed. The 9-month follow-up data indicated a 92% overall response rate, highlighting the drug's potential in treating patients with limited options. The Phase 3 program is expected to commence in H1 2026.
Read more →RLMD▲ +25.9%on this newsshared move
Unlocking Life Changing Therapies October 2025 C O R PO R AT E O VER VI E W 2025 Relmada - All rights reserved Disclosures The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward - looking
Unlocking Life Changing Therapies October 2025 C O R PO R AT E O VER VI E W 2025 Relmada - All rights reserved Disclosures The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward - looking statements made by us or on our behalf . This press release
Read more →RLMDRelmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01
Relmada Therapeutics has appointed Dr. Max Kates to its Clinical Advisory Board to support the development of NDV-01, a treatment for non-muscle invasive bladder cancer (NMIBC). Dr. Kates, known for his leadership in the Phase 3 BRIDGE trial, will contribute his expertise as Relmada prepares to initiate the Phase 3 program for NDV-01 in the first half of 2026. This appointment aims to enhance the program's design and real-world applicability.
Read more →RLMD▼ -5.6%on this news
Unlocking Life Changing Therapies September 2025 C O R PO R AT E O VER VI E W 2025 Relmada - All rights reserved Disclosures 2 The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward - loo
The article provides an overview of Relmada's corporate strategies and future plans, specifically focusing on their therapies expected to unfold by September 2025. It emphasizes the potential for life-changing treatments that are being developed by the company. However, the text lacks specific details or insights into particular products or therapeutic areas under discussion.
Read more →RLMDRelmada Regains Compliance with Nasdaq Minimum Bid Price Requirement
Relmada Therapeutics has announced that it has regained compliance with Nasdaq's minimum bid price requirement as of September 15, 2025. The company successfully maintained a minimum closing bid price of $1.00 for at least 10 consecutive business days, closing the matter with Nasdaq. As a result, Relmada's stock will continue to be traded on the Nasdaq Capital Market.
Read more →RLMDRelmada Issues Mid-Year CEO Letter to Shareholders
Relmada Therapeutics has issued a mid-year letter highlighting significant progress in its clinical programs. The company reported a 91% complete response rate for NDV-01 in Phase 2 trials and is preparing for a Phase 3 trial in 2026. Additionally, sepranolone shows promise for treating Prader-Willi Syndrome, with a Phase 2 study planned for 2026. The CEO expressed optimism about the company's future and ongoing developments.
Read more →RLMDRelmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC
Relmada Therapeutics reported a 91% overall response rate for NDV-01 in a Phase 2 study for non-muscle invasive bladder cancer (NMIBC). The company is preparing to initiate a Phase III trial in the first half of 2026 and plans to start a Phase 2 study for sepranolone in Prader-Willi syndrome. Financial results for Q2 2025 were also disclosed during the announcement.
Read more →RLMDRelmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025
Relmada Therapeutics, a clinical-stage biotechnology company, will report its second quarter 2025 financial results on August 7, 2025. The company will host a conference call and webcast to discuss these results and recent business progress. Relmada focuses on developing therapies for oncology and central nervous system conditions.
Read more →RLMDRelmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01
Relmada Therapeutics has appointed Dr. Yair Lotan as Chair of its Clinical Advisory Board to support the development of NDV-01, a treatment for non-muscle invasive bladder cancer (NMIBC). The Phase 3 trial for NDV-01 is expected to begin in the first half of 2026, building on promising Phase 2 results presented at the AUA 2025. Dr. Lotan's extensive experience in bladder cancer care will be instrumental in shaping the clinical development strategy for this innovative therapy.
Read more →RLMDRelmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology
Relmada Therapeutics has appointed Dr. Raj S. Pruthi as Chief Medical Officer-Urology. Dr. Pruthi brings over 25 years of experience in urologic oncology and clinical trials. His expertise will be crucial as the company prepares to initiate a Phase 3 trial for its lead program, NDV-01, aimed at treating non-muscle invasive bladder cancer (NMIBC). Positive Phase 2 data for NDV-01 was recently presented at the AUA 2025 meeting.
Read more →RLMD▼ -5.1%on this news
Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Relmada Therapeutics reported strong first quarter 2025 financial results alongside promising data for its Phase 2 trial of NDV-01, showing a 90% overall response rate in bladder cancer. The company plans to begin a Phase III registration trial in 2026 and is set to initiate a Phase 2 study for sepranolone targeting Prader-Willi syndrome. Despite an increase in net cash used in operations, the reduced operational loss compared to the prior year suggests potential improvement in financial management. They are focusing on advancing their clinical pipeline to capture large, underserved markets.
Read more →RLMD▲ +5.6%on this news· ran to +22% by day 1shared move
Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
Relmada Therapeutics, Inc. has announced it will report its financial results for the first quarter of 2025 on May 12, 2025. The company, based in Coral Gables, Florida, will host a conference call and webcast to discuss these results along with recent business progress. Relmada is a clinical-stage biotechnology firm focusing on breakthrough therapies, with key programs such as NDV-01 for bladder cancer under Phase 2 study and a Phase 2b preparation for sepranolone targeting compulsion-related disorders.
Read more →RLMD▼ -44.6%on this news· ran to -56% by day 1
Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 90% of patients achieved high grade disease-free status at any time point with NDV-01, demonstrating strong proof-of-concept for sustained-rel
Relmada Therapeutics announced positive initial data from its Phase 2 study of NDV-01 at the AUA2025 meeting. The treatment demonstrated a remarkable 90% of patients achieving high-grade disease-free status, supporting its further development for non-muscle invasive bladder cancer (NMIBC). The study highlighted the favorable tolerability and promising clinical activity of NDV-01, particularly in patients unresponsive to previous BCG therapies. Additionally, the drug’s easy administration and potential for outpatient use could significantly enhance treatment approaches in NMIBC.
Read more →RLMD▲ +6.9%on this news· ran to -59% by day 3shared move
Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data
Relmada Therapeutics will host a virtual key opinion leader event on April 28, 2025, to present the Phase 2 data on NDV-01 for treating high-grade non-muscle invasive bladder cancer. The event will feature experts discussing the safety and efficacy data ahead of its presentation at the American Urological Association meeting. NDV-01 is a unique investigational therapy that combines established chemotherapy agents aimed at improving patient outcomes in the bladder cancer segment, which currently faces high recurrence rates.
Read more →RLMDRelmada Therapeutics To Present NDV-01 Data at AUA2025
Relmada Therapeutics announced that it will present data on NDV-01, an innovative sustained-release therapy for high-grade non-muscle invasive bladder cancer, at the American Urology Association annual meeting in April 2025. The therapy aims to enhance efficacy while minimizing side effects through a unique delivery system designed for in-office use. The presentation is part of a Phase 2 study that explores the safety and efficacy of NDV-01, which may position it as a first-line treatment option in this patient population. The opportunity in the U.S. market is bolstered by a high prevalence of NMIBC and limited treatment alternatives, underscoring the importance of this data presentation.
Read more →RLMDRelmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update Expect Topline Phase 2 data for NDV-01 for high-grade non-muscle invasive bladder cancer (HG-NMIBC), to be presented at
Relmada Therapeutics has announced its preliminary financial results for the fourth quarter and full year of 2024 while providing a business update. The company is expecting to present topline Phase 2 data for NDV-01, targeting high-grade non-muscle invasive bladder cancer, at the upcoming AUA 2025. Additionally, Relmada is advancing sepranolone towards a Phase 2b study in Tourette syndrome. The company has a solid cash balance and continues to explore strategic product acquisitions to enhance shareholder value.
Read more →RLMDRelmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025
Relmada Therapeutics, Inc. will host a conference call and webcast on March 27, 2025, to discuss its financial results for the fourth quarter of 2024. During this event, the company will provide updates on its recent business progress. Relmada's lead investigational program, NDV-01, is currently being evaluated in a Phase 2 study for High-Grade Non-Muscle Invasive Bladder Cancer. Additionally, efforts to transition the sepranolone program for compulsion-related disorders are also underway.
Read more →RLMD▲ +6.1%on this newsshared move
Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd. NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatmen
Relmada Therapeutics has announced an exclusive licensing agreement with Trigone Pharma for NDV-01, a novel sustained-release formulation combining gemcitabine and docetaxel. This product is aimed at treating non-muscle invasive bladder cancer and is currently undergoing Phase 2 trials. First data is expected to be unveiled at the American Urological Association meeting in April 2025. The deal consists of an upfront cash payment and shares, along with future milestone payments based on the successful commercialization of NDV-01.
Read more →RLMD▼ -10%on this news
Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB Relmada purchases Sepranolone, a Phase 2b ready asset, for the treatment of Tourette syndrome (TS) and other compulsion-related
Relmada Therapeutics has acquired Sepranolone, a Phase 2b ready neurosteroid therapy, from Asarina Pharma AB for the treatment of Tourette syndrome and other compulsive disorders. The acquisition aligns with Relmada's mission to address challenging central nervous system disorders. Phase 2a clinical data indicate that Sepranolone significantly improves symptoms and quality of life without serious side effects, marking it as a potential first-line treatment option. The drug selectively targets the GABAA pathway, providing a novel approach in the management of Tourette syndrome.
Read more →RLMD▲ +5.1%on this news· ran to -19% by day 3
Relmada Therapeutics to discontinue the Reliance II and Relight Phase 3 studies of REL-1017 Relmada Therapeutics has commenced a process to explore strategic alternatives to maximize shareholder value
Relmada Therapeutics has announced the discontinuation of the Reliance II and Relight Phase 3 studies of its REL-1017 program following a review by a data monitoring committee. In conjunction with this decision, the company is beginning a process to explore strategic alternatives to maximize shareholder value. This could involve a variety of options such as asset sales or mergers. Nonetheless, the company is proceeding with the Phase 1 study of REL-P11, an investigational agent for metabolic disease.
Read more →RLMD▼ -77.3%on this newsshared move
Relmada Therapeutics Reports that Data Monitoring Committee (DMC) assessment indicates that the Phase 3 Reliance II trial is futile at its interim analysis and is unlikely to meet the primary efficacy endpoint with stati
Relmada Therapeutics announced that the interim analysis of the Phase 3 Reliance II trial, conducted by the Data Monitoring Committee (DMC), indicated the trial is unlikely to meet its primary efficacy endpoint, marking it as futile. The DMC found no new safety concerns, allowing Relmada to continue its focus on other projects, such as the Phase 1 study of REL-P11 for metabolic diseases. The company expressed disappointment at the trial results and will assess the full dataset to determine future steps for the REL-1017 program.
Read more →RLMDRelmada Therapeutics to Present at Jefferies London Healthcare Conference
Relmada Therapeutics, a late-stage biotech company focused on CNS diseases, will have CEO Sergio Traversa present at the Jefferies London Healthcare Conference on November 20, 2024. The company's lead program, REL-1017, is in late-stage development for major depressive disorder. Additionally, Relmada is exploring REL-P11, a low-dose psilocybin for metabolic disease. The replay of the presentation will be available for 90 days post-conference.
Read more →RLMDRelmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease
Relmada Therapeutics has announced the initiation of Phase 1 dosing for REL-P11, a novel psilocybin formulation targeted at metabolic diseases. This Single-Ascending Dosing study will assess the safety and pharmacokinetics of REL-P11 in both obese and normal weight subjects. Positive results from this study may lead to a Phase 2a proof-of-concept study set to begin in the first half of 2025. The company's preclinical studies indicated the treatment improved metabolic parameters without adverse CNS effects, indicating potential therapeutic value.
Read more →RLMDRelmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Relmada Therapeutics has reported its third quarter 2024 financial results, highlighting its progress in clinical development. The anticipated interim analysis for its lead candidate, REL-1017, is expected by year-end 2024, potentially stabilizing investor concerns. Additionally, the company plans to initiate a Phase 1 study for REL-P11 targeting metabolic disease. Despite a reported net loss, the company maintains a healthy cash position to support its near-term milestones.
Read more →RLMDRelmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024
Relmada Therapeutics, a late-stage biotechnology company focused on central nervous system diseases, will report its financial results for the third quarter of 2024 on November 7, 2024. The company will hold a conference call and webcast at 4:30 PM ET to discuss recent business developments. Relmada's lead program, REL-1017, is aimed at treating major depressive disorder, demonstrating potential advancements in their therapeutic approach.
Read more →RLMDRelmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Relmada Therapeutics has reported its financial results for Q2 2024, highlighting advances in its clinical programs. The company remains on track to complete enrollment for its Phase 3 Reliance II study by the end of the year, with interim results expected shortly thereafter. Additionally, preparations for a Phase 1 study of REL-P11 are underway for potential metabolic treatments. However, the company continues to face substantial net losses despite a decrease in expenses.
Read more →RLMD▼ -5.8%on this news· ran to -36% by day 3shared move
Relmada Therapeutics to Report Second Quarter 2024 Financial Results on August 7, 2024
Relmada Therapeutics, Inc. has scheduled a conference call and webcast for August 7, 2024, at 4:30 PM ET to reveal its financial results for Q2 2024. The company, which specializes in therapies for central nervous system diseases, particularly major depressive disorder, aims to share recent business developments. This event demonstrates Relmada's commitment to transparency and investor relations.
Read more →RLMDRelmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
Relmada Therapeutics, Inc. has announced a corporate update and preliminary financial results for Q4 and full year 2023. The company is advancing its Phase 3 program for REL-1017, with anticipated top line data expected in the second half of 2024. Additionally, it plans to initiate a Phase 1 trial for its low dose psilocybin program (REL-P11) in obese patients this year. However, the company faces challenges with a reported net loss of nearly $99 million in 2023.
Read more →RLMD▼ -31.7%on this news
Relmada Therapeutics Provides Corporate Update Company Well-Positioned for a Pivotal 2024 with Multiple Key Clinical Development Milestones Anticipated Relmada's Strong Balance Sheet to Support the Company Through All of
Relmada Therapeutics has provided a corporate update indicating that it is well-positioned for an important year in 2024, with multiple clinical development milestones on the horizon. Significant operational progress has been achieved in the ongoing Phase 3 program for REL-1017, aimed at treating major depressive disorder. The company is also advancing its metabolic psilocybin program, which has demonstrated therapeutic potential in pre-clinical studies. A strong financial position is expected to support these initiatives throughout the year.
Read more →RLMDRelmada Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
Relmada Therapeutics has provided a corporate update along with financial results for Q3 2023. The company is advancing its Phase 3 trials for REL-1017, targeting major depressive disorder, and has commenced a new Phase 3 study called Relight. They reported progress in enrolling patients and encouraging findings from an open-label safety study. Additionally, promising preclinical data for a non-psychedelic psilocybin treatment for steatotic liver disease was highlighted, with plans to initiate a Phase 1 trial in early 2024.
Read more →RLMDRelmada Therapeutics to Present New Preclinical Data on its Psilocybin Program at AASLD The Liver Meeting 2023 - Low-dose psilocybin generated statistically significant reductions in liver fat content, plasma glucose lev
Relmada Therapeutics announced new preclinical data on its psilocybin program, indicating beneficial effects in treating metabolic dysfunction-associated steatotic liver disease (MASLD). During the study, low-dose psilocybin showed statistically significant reductions in liver fat and improvements in metabolic parameters in rodent models. The company plans to initiate human trials with its modified-release formulation of psilocybin in early 2024, targeting obesity and metabolic disorders, as current treatments are lacking. Experts are optimistic about the implications of these findings for future therapeutic approaches.
Read more →RLMD▲ +8.7%on this newsshared move
Targeting Major Advances in the Treatment of CNS Disorders October 10 th , 2023 2023 Relmada - All rights reserved D i sc lo s u r es 2 Certain statements contained in this presentation or in other documents of Relmada T
On October 10, 2023, Relmada highlighted its continuous efforts to make significant advances in the treatment of central nervous system (CNS) disorders. The company aims to address complex medical challenges associated with these conditions. Relmada's focus on innovation suggests a positive outlook for future therapies and improved patient outcomes.
Read more →RLMDTargeting Major Advances in the Treatment of CNS Disorders October 4 th , 2023 2023 Relmada - All rights reserved Disclosures 2 Certain statements contained in this presentation or in other documents of Relmada Therapeut
Relmada Therapeutics is making significant strides in advancing treatment options for central nervous system (CNS) disorders. On October 4, 2023, the company presented developments that underline its commitment to addressing these complex health issues. The presentation highlighted specific advances, yet details on clinical outcomes were not provided. Overall, the focus remains on innovation in CNS therapeutics.
Read more →RLMD▲ +5.1%on this news· ran to +25% by day 3
Targeting Major Advances in the Treatment of CNS Disorders August 10 th , 2023 2023 Relmada - All rights reserved Disclosures 2 Certain statements contained in this presentation or in other documents of Relmada Therapeut
Relmada Therapeutics has presented a focus on major advances in the treatment of central nervous system (CNS) disorders. The updates were shared on August 10, 2023, showcasing the company's commitment to innovative therapies in this critical area. This information underscores the potential for future developments in addressing these complex medical conditions.
Read more →RLMDRelmada Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
Relmada Therapeutics, Inc. has announced a corporate update and financial results for the second quarter of 2023. The company is making progress in its Phase 3 clinical trial for REL-1017 as a treatment for major depressive disorder, with expected trial completions in 2024. Despite these advancements, Relmada reported a net loss of approximately $25.3 million for the quarter, highlighting ongoing financial challenges. Future funding appears adequate to support their development plans.
Read more →RLMDTargeting Major Advances in the Treatment of CNS Disorders May 15 th , 2023 202 3 Relmada - All rights reserve d Disclosures 2 Certain statements contained in this presentation or in other documents of Relmada Therapeuti
Relmada Therapeutics is advancing its lead program, REL-1017, which is currently in Phase 3 trials for Major Depressive Disorder (MDD). The company highlights the promising efficacy and safety profile of REL-1017 based on positive Phase 2 data, indicating its potential as a rapid-acting treatment. Despite these advancements, the company notes that uncertainties in regulatory approval may pose a risk to its future performance. Investors are encouraged to review the company’s risk factors as outlined in SEC filings.
Read more →RLMDRelmada Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
Relmada Therapeutics, Inc. provided a corporate update and reported its financial results for the first quarter of 2023. The company is focused on the late-stage development of REL-1017 for major depressive disorder, with enrollment in ongoing studies progressing and a completion target set for the first half of 2024. Revisions to trial protocols and a new internal clinical development team are expected to enhance outcomes. Notably, the company recorded a net loss of $26.3 million for the quarter but remains optimistic about funding and trial execution.
Read more →RLMD▼ -6%on this news· ran to -16% by day 3
Targeting Major Advances in the Treatment of CNS Disorders April 19th, 2023 2023 Relmada - All rights reserved Disclosures 2 Certain statements contained in this presentation or in other documents of Relmada Therapeutics
Relmada Therapeutics has announced advancements in the treatment of central nervous system (CNS) disorders as of April 19, 2023. The company is focusing on innovative therapeutic approaches to address major challenges in this area of healthcare. This initiative represents a critical step towards improving treatment options for patients suffering from CNS conditions.
Read more →RLMDRelmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results
Relmada Therapeutics provided a corporate update and preliminary financial results for Q4 and full-year 2022. CEO Sergio Traversa highlighted the company's analysis of the divergent results from their Phase 3 trial concerning REL-1017, ensuring changes to enhance future trials. Despite a net loss reported for 2022, the company remains optimistic about the drug's potential and is moving forward with plans to amend existing studies and initiate a new trial. Relmada's strategy includes focusing on the reliable identification of clinical sites and patients to increase the efficacy of its trials.
Read more →RLMD▲ +15.3%on this news
RELMADA THERAPEUTICS, INC. 2222 Ponce De Leon Blvd., 3 rd Floor Coral Gables, FL 33134
Relmada Therapeutics has welcomed Fabiana Fedeli to its Board of Directors effective January 12, 2023. She will receive an annual director fee of $66,000 along with 200,000 stock options, which are subject to a vesting schedule contingent upon shareholder approval. Additionally, Fedeli will serve on both the Audit and Compensation Committees, which highlights her role in the company's governance. The agreement details her tenure, which extends until her resignation or the election of a successor.
Read more →RLMDRelmada Therapeutics Appoints CNS Therapeutic Expert Cedric O'Gorman MD as Chief Medical Officer
Relmada Therapeutics has appointed Dr. Cedric O'Gorman as Chief Medical Officer to lead their medical and regulatory functions. Dr. O'Gorman, who has extensive experience in CNS therapeutics, will oversee the development of the company's late-stage program for REL-1017, aimed at addressing major depressive disorder. His appointment brings significant expertise that relates directly to the company’s goals as they navigate upcoming FDA discussions and potential clinical trials.
Read more →RLMDRelmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder Company to Host Conference Call Today
Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder Company to Host Conference Call Today, December 7, 2022, at 5:00 PM ET CORAL GABLES, Fla., December 7, 2022 /PRNewswire/ -- Re
Read more →RLMDTargeting Major Advances in Treatment of CNS Disorders November 11th , 2022 I Nasdaq: RLMD 1 Disclosures Certain statements contained in this presentation or in other documents of Relmada Therapeutics, Inc. (the "Company
Targeting Major Advances in Treatment of CNS Disorders November 11th , 2022 I Nasdaq: RLMD 1 Disclosures Certain statements contained in this presentation or in other documents of Relmada Therapeutics, Inc. (the "Company"), along with certain statements that may be made by manag
Read more →RLMDRelmada Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results CORAL GABLES, Fla., Nov. 10, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CN
Read more →RLMD▼ -79.6%on this news
Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder RELIANCE I and II Adjunctive MDD Trials Continue to Advance
Relmada Therapeutics Announces Top-line Results RELIANCE III Trial for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder RELIANCE I and II Adjunctive MDD Trials Continue CORAL GABLES, Fla., Oct. 13, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasd
Read more →RLMDRelmada Therapeutics Announces Completion of Treatment in Company's Registrational Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for Major Depressive Disorder
Relmada Therapeutics Announces Completion of Treatment in Company's Registrational Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for Major Depressive Disorder CORAL GABLES, Fla., September 20, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-st
Read more →RLMD▼ -7.7%on this news· ran to -18% by day 3
Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results CORAL GABLES, Fla., May 5 th , 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD) ("Relmada," the "Company," "we
Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results CORAL GABLES, Fla., May 5th, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD) ("Relmada," the "Company," "we," "us, "our"), a late-stage biotechnology company address
Read more →RLMDRelmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results CORAL GABLES, Fla., March 23, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central ne
Read more →RLMDTargeting Major Advances in Treatment of CNS Disorders
Targeting Major Advances in Treatment of CNS Disorders March 7, 2022 I Nasdaq: RLMD 1 Disclosures Certain statements contained in this presentation or in other documents of Relmada Therapeutics, Inc. (the "Company"), along with certain statements that may be made by management o
Read more →RLMD▲ +6.7%on this news
Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Ketamine for Abuse Potential - All doses of REL-1017, including the maximum tolerated dose, demonstrated a statistically significant differe
Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Ketamine for Abuse Potential - All doses of REL-1017, including the maximum tolerated dose, demonstrated a statistically significant difference in abuse potential vs. ketamine (p-values <0.05) - A
Read more →RLMDRelmada Therapeutics Announces Publication of REL-1017 Phase 2 Study Results in The American Journal of Psychiatry - Manuscript further details findings from study assessing REL-1017 as adjunctive treatment for MDD - Pri
Relmada Therapeutics Announces Publication of REL-1017 Phase 2 Study Results in The American Journal of Psychiatry CORAL GABLES, Fla., Dec. 22, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the centra
Read more →RLMDRelmada Therapeutics Announces Proposed Public Offering of Common Stock
CORAL GABLES, Fla., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced its intention to offer and sell $100 million of shares of its common stock
Read more →RLMDTargeting Major Advances in Treatment of CNS Disorders November 2021 I Nasdaq: RLMD 1 Disclosures Certain statements contained in this presentation or in other documents of Relmada Therapeutics, Inc. (the "Company"), alo
Targeting Major Advances in Treatment of CNS Disorders November 2021 I Nasdaq: RLMD 1 Disclosures Certain statements contained in this presentation or in other documents of Relmada Therapeutics, Inc. (the "Company"), along with certain statements that may be made by management o
Read more →RLMDRelmada Therapeutics Provides Regulatory and Development Updates on Ongoing Late-Stage Clinical Program for REL-1017 for Treatment of Major Depressive Disorder Relmada is actively enrolling patients in RELIANCE III, a Mo
Relmada Therapeutics Provides Regulatory and Development Updates on Ongoing Late-Stage Clinical Program for REL-1017 for Treatment of Major Depressive Disorder Relmada is actively enrolling patients in RELIANCE III, a Monotherapy Registrational Phase 3 Study FDA Confirms Relm
Read more →RLMDRelmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results Phase 3 Program for REL-1017 as Adjunctive Treatment for Major Depressive Disorder Initiated Multiple Data Re
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results Phase 3 Program for REL-1017 as Adjunctive Treatment for Major Depressive Disorder Initiated Multiple Data Readouts Anticipated Over Next Several Company to Host Co
Read more →RLMDAbstract to be presented at the ASPET Annual Meeting at Experimental Biology on April 27 to
Abstract to be presented at the ASPET Annual Meeting at Experimental Biology on April 27 to April 30, 2021 Title: REL-1017 (esmethadone) did not produce initial or cumulative neurotoxic effects or other evidence of damage to cortical neurons The objective of this study was to
Read more →RLMDWe have recently initiated two separate human abuse potential studies, REL-1017-120 and REL-1017-124, using 100 mg oral ketamine and 40 mg oral oxycodone as positive controls, respectively. While the oxycodone study is a
We have recently initiated two separate human abuse potential studies, REL-1017-120 and REL-1017-124, using 100 mg oral ketamine and 40 mg oral oxycodone as positive controls, While the oxycodone study is advancing as planned and is expected to generate top line data in the se
Read more →RLMDCorporate Presentation I Targeting Major Advances in Treatment of CNS Disorders December 2020 I Nasdaq: RLMD 2 0 2 0 C o r p o r a te P r e s e n t a t i o n I 2 Disclosures Certain statements contained in this presentat
2020 Corporate Presentation I Targeting Major Advances in Treatment of CNS Disorders December 2020 I Nasdaq: RLMD 2 0 2 0 C o r p o r a te P r e s e n t a t i o n I 2 Disclosures Certain statements contained in this presentation or in other documents of Relmada Therapeutics, Inc
Read more →RLMDCorporate Presentation I Targeting Major Advances in Treatment of CNS Disorders November 2020 I Nasdaq: RLMD 2020 Corporate Presentation I Disclosures Certain statements contained in this presentation or in other documen
2020 Corporate Presentation I Targeting Major Advances in Treatment of CNS Disorders November 2020 I Nasdaq: RLMD 2020 Corporate Presentation I Disclosures Certain statements contained in this presentation or in other documents of Relmada Therapeutics, Inc . (the "Company"), alo
Read more →RLMDRelmada Therapeutics Expands R&D Team, Appoints Paolo Manfredi, M.D., as Acting Chief Scientific Officer, Marco Pappagallo, M.D., as Acting Chief Medical Officer and Updates R&D Milestones NEW YORK, New York, October, 27
Therapeutics Expands R&D Team, Appoints Paolo Manfredi, M.D., as Acting Chief Scientific Officer, Marco Pappagallo, M.D., as Acting Chief Medical Officer and Updates R&D Milestones New York, October, 27, 2020 (PR Newswire) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinic
Read more →RLMDCorporate Presentation I Targeting Major Advances in Treatment of CNS Disorders June 2020 I Nasdaq: RLMD 2020 Corporate Presentation I Disclosures Certain statements contained in this presentation or in other documents o
2020 Corporate Presentation I Targeting Major Advances in Treatment of CNS Disorders June 2020 I Nasdaq: RLMD 2020 Corporate Presentation I Disclosures Certain statements contained in this presentation or in other documents of Relmada Therapeutics, Inc . (the "Company"), along w
Read more →RLMDRelmada Therapeutics Strengthens Board
Relmada Therapeutics Strengthens Board of Directors with Appointments of Life Sciences Industry Veterans, Eric Schmidt, Ph.D., and John Glasspool NEW YORK, December 20, 2019 - Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for t
Read more →RLMDCAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Current Report on Form 8-K (this Report) contains forward looking statements that involve risks and uncertainties. All statements other than statements of histori
NOTE REGARDING FORWARD-LOOKING STATEMENTS Current Report on Form 8-K (this Report) contains forward looking statements that involve risks and uncertainties. All statements other than statements of historical fact contained in this Report, including statements regarding future e
Read more →RLMDRELMADA THERAPEUTICS, INC. Audited Financial Statements As of
RELMADA THERAPEUTICS, Audited Financial Statements As of June 30, 2019 and 2018 and for the years then ended RELMADA THERAPEUTICS, (INDEX TO FINANCIAL STATEMENTS) Page Report of Independent Registered Public Accounting Firm 3 Consolidated Balance Sheets as of June 30, 2019
Read more →RLMDRelmada Therapeutics, Inc Proforma Balance sheet
June 30, 2019 Without Impact of Financing Pro Forma Adjustments Resulting from Financings Post Pro Forma Adjustments Assets: Current $ 9,984,381 $ 1,275,750 $ 11,260,131 Non-current $ 235,352 $ 235,352 Total Assets $ 10,219,733 $ 1,275,750 $
Read more →RLMDRelmada Therapeutics, Inc. Proforma Balance Sheet
Relmada Therapeutics, Inc. Proforma Balance Sheet March 31, 2019 Without Impact of Financings Pro Forma Adjustments Resulting from Financings Post Pro- Forma Adjustments ($ in thousands) Assets: Current $ 2,330,300 $ 10,855,700 a $ 13,186,000 b Non-cur
Read more →RLMDTicker Symbol OTCQB:RLMD Innovations in Central Nervous System Diseases
Ticker Symbol OTCQB:RLMD Innovations in Central Nervous System Diseases April 4, 2018 Targeting Major Advances in Treatment of CNS Disorders Ticker Symbol OTCQB:RLMD Forward Looking Statements Certain statements contained in this presentation or in other documents of Relmada The
Read more →RLMDRelmada Therapeutics Acquires Global Rights to Develop and Market Dextromethadone for Treatment of Disorders of the Nervous System Agreement positions company to advance dextromethadone program to its full potential targ
Relmada Therapeutics Acquires Global Rights to Develop and Market Dextromethadone for Treatment of Disorders of the Nervous System Agreement positions company to advance dextromethadone program to its full potential targeting a wide range of neurological conditions including c
Read more →RLMDTherapeutics Announces Settlement of Legal Action with Laidlaw & Company
Therapeutics Announces Settlement of Legal Action with Laidlaw & Company YORK, May 18 2017 - Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, and Laidlaw & Company (UK) Ltd.
Read more →RLMDJEFFREY S. RUGG, ESQ., Bar # 10978 jrugg@bhfs.com MAXIMILIEN D. FETAZ, ESQ., Bar # 12737 mfetaz@bhfs.com Brownstein Hyatt Farber Schreck, LLP 100 North City Parkway, Suite 1600 Las Vegas, Nevada 89106 Telephone: 702.382.
STATES DISTRICT COURT RELMADA THERAPEUTICS, INC. , a Nevada corporation, Case No.: 2:15-cv-2338-JCM-CWH Plaintiff, [PROPOSED] SECOND AMENDED COMPLAINT v. (1) Breach of Fiduciary Duty LAIDLAW & COMPANY (UK) LTD., a foreign corporation, MATTHEW D. EITNER , an individual and cit
Read more →RLMDRelmada Therapeutics' Michael Becker Interviewed by The Life Sciences Report
SAN FRANCISCO, CA--(Marketwired - April 21, 2016) - To treat chronic pain without risk of addiction is to straddle a knife's edge. But Relmada Therapeutics Inc. (OTCQB: RLMD) has a small fleet of compounds in development that address both sides of an issue that has become a news
Read more →RLMDTherapeutics Announces Results of Annual Meeting of Stockholders
Therapeutics Announces Results of Annual Meeting of Stockholders Elect All of the Company's Director Nominees YORK, Dec. 30, 2015 -- Relmada Therapeutics, Inc. (OTCQB: RLMD) ("Relmada" or "the Company"), a clinical-stage company developing novel therapies for the treatment of
Read more →RLMDBrownstein Hyatt Farber Schreck, LLP 100 North City parkway, Suite 1600 Las Vegas, NV 89106 (702) 382-2101 JEFFREY S. RUGG, ESQ., Bar # 10978 jrugg@BHFS.com Brownstein Hyatt Farber Schreck, LLP 100 North City Parkway, Su
Hyatt Farber Schreck, LLP North City parkway, Suite 1600 STATES DISTRICT COURT CONSIDERATION of the Motion for Preliminary Injunction filed by Plaintiff Relmada Therapeutics, Inc. ("Relmada") for a preliminary injunction against Defendants Laidlaw & Company (UK) Ltd., Matthe
Read more →RLMDPharmaceutical Industry Leader James Dolan Joins Relmada Therapeutics Advisory Team Former Purdue Pharma Senior Vice President of Licensing and Business Development Brings More than 36 Years of Life Sciences Industry Exp
Industry Leader James Dolan Joins Relmada Therapeutics Advisory Team Purdue Pharma Senior Vice President of Licensing and Business Development Brings More than 36 Years of Life Sciences Industry Experience, Including Expertise in Business Development and Licensing of Pain Manag
Read more →RLMDBrownstein Hyatt Farber Schreck, LLP 100 North City parkway, Suite 1600 Las Vegas, NV 89106 (702) 382-2101 JEFFREY S. RUGG, ESQ., Bar # 10978 jrugg@bhfs.com MAXIMILIEN D. FETAZ, ESQ., Bar # 12737 mfetaz@bhfs.com Brownste
Hyatt Farber Schreck, LLP North City parkway, Suite 1600 STATES DISTRICT COURT CONSIDERATION of the Motion For Temporary Restraining Order Without Notice and Preliminary Injunction filed by Plaintiff Relmada Therapeutics, Inc. ("Relmada") for a temporary restraining order and
Read more →RLMDRelmada Therapeutics Announces Additional Information Regarding Positive Topline Results for Proof-of-Concept Study with BuTab Absolute Bioavailability of BuTab Relative to Intravenous Administration Exceeded Published D
Therapeutics Announces Additional Information Regarding Positive Topline Results for Proof-of-Concept Study with BuTab Bioavailability of BuTab Relative to Intravenous Administration Exceeded Published Data with Non-Modified Buprenorphine; Compares Favorably with Currently Ma
Read more →RLMDRelmada Therapeutics Announces Positive Topline Results for Proof-of-Concept Study with BuTab Conference Call and Webcast Scheduled at 8:30a.m. ET on
Therapeutics Announces Positive Topline Results for Proof-of-Concept Study with BuTab Call and Webcast Scheduled at 8:30a.m. ET on December 10, 2015 YORK, December 9, 2015 - Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the t
Read more →RLMDBrownstein Hyatt Farber Schreck, LLP 100 North City parkway, Suite 1600 Las vegas, NV 89106 (702) 382-2101 JEFFREY S. RUGG, ESQ., Bar # 10978 jrugg@bhfs.com MAXIMILIEN D. FETAZ, ESQ., Bar # 12737 mfetaz@bhfs.com Brownste
Hyatt Farber Schreck, LLP North City parkway, Suite 1600 STATES DISTRICT COURT Relmada Therapeutics, Inc. moves for the entry of a temporary restraining order without notice and preliminary injunction pending the adjudication on the merits of this case. Hyatt Farber Schreck,
Read more →RLMDRelmada Therapeutics Strengthens its Board of Directors with the Appointment of Maged Shenouda and Paul Kelly Additions Bring Significant Levels of Experience in Diverse Areas Including Finance, Corporate Development and
Therapeutics Strengthens its Board of Directors with the Appointment of Maged Shenouda and Paul Kelly Bring Significant Levels of Experience in Diverse Areas Including Finance, Corporate Development and Product Licensing YORK, November 12, 2015 - Relmada Therapeutics, Inc. (OT
Read more →RLMDRelmada Therapeutics Responds to 13D Filing By Laidlaw
Relmada Therapeutics Responds to 13D Filing By Laidlaw NEW YORK, November 5, 2015 - Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today issued the following statement in response to the Schedul
Read more →RLMDRelmada Therapeutics Announces Management Promotions Company Expands Roles for Seasoned Industry Professionals to Support Advancement of Multiple Clinical Stage Development Programs
Therapeutics Announces Management Promotions Expands Roles for Seasoned Industry Professionals to Support Advancement of Multiple Clinical Stage Development Programs YORK, October 5, 2015 - Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel ther
Read more →RLMDRelmada Therapeutics Appoints Charles J. Casamento to Its Board of Directors Seasoned executive has more than four decades of industry experience
Therapeutics Appoints Charles J. Casamento to Its Board of Directors Seasoned executive has more than four decades of industry experience NEW YORK, July 16, 2015 - Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment
Read more →RLMDLEASE AGREEMENT AGREEMENT OF LEASE Between GP 275 OWNER, LLC, Landlord, and RELMADA THERAPEUTICS, INC., Tenant. Premises: Suite 702 275 Madison Avenue New York, New York LEASE INFORMATION SUMMARY I. LEASE DATE
RELMADA THERAPEUTICS, INC., LEASE INFORMATION SUMMARY I. LEASE DATE: June 9, 2015 II. PARTIES AND ADDRESSES: A. Landlord: GP 275 Owner, LLC B. Landlord's Address for Notices c/o RFR Realty LLC 390 Park Avenue New York, New York 10022 with a copy to: Katsky Korins LLP 605 Thi
Read more →RLMDRelmada Therapeutics Set for Busy 2015 in Clinical Trials Developing Drugs for the Lucrative Pain Market
NEW YORK, NY--(Marketwired - April 02, 2015) - Relmada Therapeutics, Inc. (OTCQB: RLMD) has quite a busy 2015 ahead of it in the clinic. The pharmaceutical company has stepped up its work in a big way, and the latest news out of Relmada has it continuing to apply its unique model
Read more →RLMDRelmada Therapeutics Adds $15 Million in Capital to Expedite Development of Pain Treatment Drugs
NEW YORK, NY--(Marketwired - October 29, 2014) - Relmada Therapeutics, Inc. (OTCQB: RLMD), a biopharmaceutical firm with four novel pain treatment drugs currently under development in its pipeline, received a healthy injection of more than $15 million in capital last week that wi
Read more →RLMDRELMADA THERAPEUTICS REINFORCES BALANCE SHEET WITH $15.2 MILLION FROM EXERCISE OF WARRANTS Additional Capital Enable Company to Achieve Additional Milestones in its Business Plan New York, NY
THERAPEUTICS REINFORCES BALANCE SHEET WITH $15.2 MILLION FROM EXERCISE OF WARRANTS Capital Enable Company to Achieve Additional Milestones in its Business Plan York, NY October 16, 2014 - Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage company developing novel thera
Read more →RLMDRelmada Therapeutics, Inc. Provides Its First Corporate Update as a Public Company Material Progress on All Fronts in 2014 Leave Company Strongly Positioned to Unlock the Value of its Robust Pain Product Pipeline New Yor
Therapeutics, Inc. Provides Its First Corporate Update as a Public Company Progress on All Fronts in 2014 Leave Company Strongly Positioned to Unlock the Value of its Robust Pain Product Pipeline York, NY September 9, 2014 - Relmada Therapeutics, Inc., (OTCBB: RLMD), a Nevada c
Read more →RLMDRelmada Therapeutics, Inc. Completes Name Change and Announces New Ticker The Company's New Ticker Is RLMD New York, NY
Therapeutics, Inc. Completes Name Change and Announces New Ticker Company's New Ticker Is RLMD York, NY August 6, 2014 - Relmada Therapeutics, Inc., (OTCBB: RLMD), a Nevada corporation (the "Company"), a clinical-stage company developing novel therapies for the treatment of c
Read more →RLMDRELMADA THERAPEUTICS SUCCESSFULLY COMPLETES OFFERINGS TOTALING $28 MILLION IN CONNECTION WITH GOING PUBLIC TRANSACTION PRWeb - June 16 th , 2014 Relmada Therapeutics and Camp Nine Expect Offering Proceeds to Enable It to
RELMADA THERAPEUTICS SUCCESSFULLY COMPLETES OFFERINGS TOTALING $28 MILLION IN CONNECTION WITH GOING PUBLIC TRANSACTION PRWeb - June 16th, 2014 Relmada Therapeutics and Camp Nine Expect Offering Proceeds to Enable It to Achieve Significant Milestones While Advancing It's Drug D
Read more →RLMDThe unaudited pro forma information below gives effect to the share exchange between Camp Nine, Inc. and Relmada Therapeutics, Inc. as if it had been consummated as of
The unaudited pro forma information below gives effect to the share exchange between Camp Nine, Inc. and Relmada Therapeutics, Inc. as if it had been consummated as of December 31, 2013. The unaudited pro forma information has been derived from the historical Financial Statements
Read more →Competitive Position
How RLMD ranks across every disease it competes inCompetitive Position is a premium feature
See how RLMD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial